Prostate cancer immunotherapy: Improving clinical outcomes with a multi-pronged approach.
Prostate cancer immunotherapy: Improving clinical outcomes with a multi-pronged approach.
复制标题
DOI：
10.1016/j.xcrm.2023.101199
复制
发表时间：
2023-10-17
影响因子：
14.3
通讯作者：
Mahajan, Nupam P.
中科院分区：
文献类型：
--
作者：
Sridaran, Dhivya;Bradshaw, Elliot;Deselm, Carl;Pachynski, Russell;Mahajan, Kiran;Mahajan, Nupam P.
近年来，由于一些患者的肿瘤清除效果显着，癌症免疫疗法获得了关注。尽管免疫检查点阻断（ICB）在多种恶性肿瘤中取得了显着的成功，但免疫系统参与靶向前列腺癌（PCa）治疗仍处于起步阶段。多种因素导致有限的反应，包括PCa的异质性，冷的肿瘤微环境和少量的新抗原。正在投入大量精力改善基于免疫的PCa疗法。本文综述了免疫疗法治疗前列腺癌的现状，讨论了多种免疫方式，包括疫苗，过继转移T细胞和双特异性T细胞增殖剂，其中一些正在进行临床试验。此外，本综述还重点介绍了具有免疫调节特性的新兴机制小分子酪氨酸激酶抑制剂，无论是作为单一药物还是与其他免疫疗法联合使用，都有可能改善临床结局。
Cancer immunotherapy has gained traction in recent years owing to remarkable tumor clearance in some patients. Despite the notable success of immune checkpoint blockade (ICB) in multiple malignancies, engagement of the immune system for targeted prostate cancer (PCa) therapy is still in its infancy. Multiple factors contribute to limited response, including the heterogeneity of PCa, the cold tumor microenvironment, and a low number of neoantigens. Significant effort is being invested in improving immune-based PCa therapies. This review is a summary of the status of immunotherapy in treating PCa, with a discussion of multiple immune modalities, including vaccines, adoptively transferred T cells, and bispecific T cell engagers, some of which are undergoing clinical trials. In addition, this review also focuses on emerging mechanism-based small-molecule tyrosine kinase inhibitors with immune modulatory properties that, either as single agents or in combination with other immunotherapies, have the potential to improve clinical outcomes.
登录
查看更多内容
影响因子：
13.3
作者：
Chouhan, Surbhi;Sawant, Mithila;Weimholt, Cody;Luo, Jingqin;Sprung, Robert W.;Terrado, Mailyn;Mueller, David M.;Earp, H. Shelton;Mahajan, Nupam P.
通讯作者：
Mahajan, Nupam P.
影响因子：
14.9
作者：
Almeida LG;Sakabe NJ;deOliveira AR;Silva MC;Mundstein AS;Cohen T;Chen YT;Chua R;Gurung S;Gnjatic S;Jungbluth AA;Caballero OL;Bairoch A;Kiesler E;White SL;Simpson AJ;Old LJ;Camargo AA;Vasconcelos AT
通讯作者：
Vasconcelos AT
影响因子：
3.4
作者：
Cibull, TL;Jones, TD;Cheng, L
通讯作者：
Cheng, L
影响因子：
11.5
作者：
Deegen, Petra;Thomas, Oliver;Bailis, Julie M.
通讯作者：
Bailis, Julie M.
影响因子：
4.5
作者：
Bissig, Christin;Hurbain, Ilse;van Niel, Guillaume
通讯作者：
van Niel, Guillaume